CollPlant Biotechnologies
CLGN
18 hedge funds and large institutions have $8.55M invested in CollPlant Biotechnologies in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
6% more funds holding
Funds holding: 17 → 18 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.04% less ownership
Funds ownership: 13.69% → 13.66% (-0.04%)
31% less capital invested
Capital invested by funds: $12.5M → $8.55M (-$3.92M)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SDJVC
St. Denis J. Villere & Co
New Orleans,
Louisiana
|
+$49.3K |
| 2 |
Brown Advisory
Baltimore,
Maryland
|
+$6.53K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$662 |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$40 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Pinnacle Associates
New York
|
-$42K |
| 2 |
BFEC
Benjamin F. Edwards & Company
St. Louis,
Missouri
|
-$27.5K |
| 3 |
PA
Parallel Advisors
San Francisco,
California
|
-$7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$5.68K |
| 5 |
First Manhattan
New York
|
-$816 |
CLGN Hedge Fund Activity: Q3 2023 in Review
18 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in CollPlant Biotechnologies (CLGN) for Q3 2023, worth a combined $8.55M — down 31% from $12.5M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CLGN positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 6 trimmed.
The largest buyer was St. Denis J. Villere & Co, adding an estimated $49.3K. The largest seller was Pinnacle Associates, cutting an estimated $42K.
- 18 institutional investors held CollPlant Biotechnologies (CLGN) as of Q3 2023, up from 17 in Q2 2023.
- Funds reported $8.55M of CollPlant Biotechnologies stock for Q3 2023, down 31% quarter-over-quarter.
- 2 funds opened new CollPlant Biotechnologies positions in Q3 2023 and 1 closed out, a net change of +1 holder.
- The largest CollPlant Biotechnologies buyer in Q3 2023 was St. Denis J. Villere & Co, an estimated $49.3K added.
- The largest CollPlant Biotechnologies seller in Q3 2023 was Pinnacle Associates, an estimated $42K sold.
Based on aggregated 13F filings for Q3 2023.